(HART) IQ Healthy Hearts - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US45409B3217 • Health

HART: Healthcare Stocks, Pharmaceuticals, Medical Devices, Biotechnology

The IQ Healthy Hearts ETF (NYSE ARCA: HART) is a passively managed exchange-traded fund designed to replicate the performance of an index developed by IndexIQ LLC, with Candriam, an affiliate of IndexIQ, serving as the index consultant. The fund tracks an index that includes equities of various market capitalizations—large-, mid-, and small-cap companies—trading in both U.S. and international markets, excluding certain emerging markets such as China, Egypt, India, Kuwait, Pakistan, Qatar, Saudi Arabia, and the United Arab Emirates. As a non-diversified fund, it may concentrate its investments in a smaller number of securities, which can lead to higher volatility compared to diversified funds.

Ticker Symbol: HART | Exchange: NYSE ARCA | Type: ETF | Country Origin: USA | ETF Category: Health

Based on the provided data, HART currently trades at $31.05, with a 20-day average volume of 1200 shares. Its short-term moving averages (SMA 20: $31.85, SMA 50: $32.02) suggest recent price stability, while the 200-day SMA ($31.71) indicates a slightly lower long-term trend. The Average True Range (ATR) of 0.25 reflects low volatility, suggesting minimal price fluctuations. The funds assets under management (AUM) stand at $9.32 million, a relatively small size for an ETF, which may impact liquidity.

3-Month Forecast: - - The funds moving averages (SMA 20: $31.85, SMA 50: $32.02, SMA 200: $31.71) suggest a potential sideways trend in the near term. - The low ATR of 0.25 indicates that volatility is likely to remain subdued. - The small average volume of 1200 shares could lead to limited market impact but may also result in wider bid-ask spreads. - - - With an AUM of $9.32 million, the funds liquidity may remain constrained, which could affect its ability to track the underlying index closely. - As a non-diversified fund, HART may exhibit heightened sensitivity to sector-specific developments in the healthcare industry. - Overall, HART is expected to maintain its current trajectory, with minimal price movement and low volatility. However, its non-diversified nature and small AUM may make it more susceptible to market conditions and sector-specific news.

Additional Sources for HART ETF

HART ETF Overview

Market Cap in USD 9m
Category Health
TER 0.45%
IPO / Inception 2021-01-14

HART ETF Ratings

Growth Rating 45.3
Fundamental -
Dividend Rating 47.5
Rel. Strength -2.86
Analysts -
Fair Price Momentum 27.04 USD
Fair Price DCF -

HART Dividends

Dividend Yield 12m 1.34%
Yield on Cost 5y 1.72%
Annual Growth 5y 6.72%
Payout Consistency 100.0%

HART Growth Ratios

Growth Correlation 3m -49.8%
Growth Correlation 12m 35.6%
Growth Correlation 5y 78.7%
CAGR 5y 5.31%
CAGR/Max DD 5y 0.31
Sharpe Ratio 12m 0.95
Alpha -2.68
Beta 0.720
Volatility 30.34%
Current Volume 1k
Average Volume 20d 1.4k
What is the price of HART stocks?
As of April 16, 2025, the stock is trading at USD 29.56 with a total of 967 shares traded.
Over the past week, the price has changed by +4.89%, over one month by -7.13%, over three months by -4.01% and over the past year by +4.85%.
Is IQ Healthy Hearts a good stock to buy?
Partly, yes. Based on ValueRay Analyses, IQ Healthy Hearts (NYSE ARCA:HART) is currently (April 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 45.26 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HART as of April 2025 is 27.04. This means that HART is currently overvalued and has a potential downside of -8.53%.
Is HART a buy, sell or hold?
IQ Healthy Hearts has no consensus analysts rating.
What are the forecast for HART stock price target?
According to ValueRays Forecast Model, HART IQ Healthy Hearts will be worth about 29.8 in April 2026. The stock is currently trading at 29.56. This means that the stock has a potential upside of +0.64%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 29.8 0.6%